Trial Profile
A phase II open label randomized multicenter trial of TSU-68 in combination with docetaxel versus docetaxel alone in patients with metastatic breast cancer previously treated with an anthracycline.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2018
Price :
$35
*
At a glance
- Drugs Orantinib (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 09 Apr 2014 Results published in Investigational New Drugs.
- 03 Nov 2011 New trial record